Rapavir

Rapavir (JH-B10) is a selective and potent sodium taurocholate cotransporting polypeptide (NTCP) inhibitor with an IC50 value of 1.8 nM for the uptake of taurocholic acid-d4 (TCA-d4) . Rapavir exerts antiviral activity by directly binding to NTCP and blocking the entry of the virus into cells during the HBV infection phase. Rapavir is promising for research of HBV infections[1].

Product Specifications

Product Name Alternative

JH-B10

UNSPSC

12352101

Target

HBV

Related Pathways

Anti-infection

Field of Research

Infection

Smiles

O=C(COC1=CC([C@@H](CCC2=CC=C(C(OC)=C2)OC)OC([C@@H]3CCCCN3C4=O)=O)=CC=C1)N(C)CC(N[C@H](C(N([C@H](C(N[C@H](C(N(C)CC/C=C/C(OCC(C)(C4=O)C)=O)=O)CC5=CC=C(C=C5)F)=O)CC6=CC=CC=C6)C)=O)CC7=CC=C(C=C7)O)=O

Molecular Formula

C68H79FN6O15

Molecular Weight

1239.38

References & Citations

[1]He J, et al. Rapavir, a novel inhibitor of sodium taurocholate cotransporting polypeptide, potently blocks hepatitis B virus entry. Signal Transduct Target Ther. 2025 Apr 23;10 (1) :130.